Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology announced positive results from its Phase II TBCRC 022 Trial in patients with HER2-positive metastatic breast cancer with brain metastases at the 2017 ASCO Annual Meeting.

Puma Biotechnology, Inc.